NCT06796868已完成2 期
A Multicenter, Randomized , Double-blind, Parallel, Placebo-controlled Design Clinical Trial of GW117 Tablets
Beijing Greatway Pharmaceutical Technology Co.,Ltd.17 个研究点 分布在 1 个国家目标入组 280 人开始时间: 2022年7月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 280
- 试验地点
- 17
- 主要终点
- The change in Hamilton Depression Scale-17(HAMD-17) total score from baseline
研究概览
简要总结
The study aims to evaluate the efficacy and safety of GW117 Tablets compared to placebo in adults participants with MDD over a period of 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Outpatients aged 18 to 65 years (including both limits), either male or female;
- •Meet the diagnostic criteria for depression in DSM-5 (the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders), without psychotic symptoms;
- •Have a total score of ≥ 22 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at both screening and baseline visits;
- •Have a Clinical Global Impression - Severity (CGI-S) score of ≥ 4 at both screening and baseline visits;
- •Voluntarily participate in this trial and sign the informed consent form, and be able to comply with the planned visits, treatment plan, laboratory tests and other research procedures.
排除标准
- •Allergic constitution (such as those allergic to two or more drugs or foods) or known to be allergic to similar products like agomelatine;
- •Have previously received adequate and full-course treatment with agomelatine but showed no effect, or treatment-resistant depression (those who have used at least two antidepressants in adequate and full-course treatment but still showed no effect);
- •HAM-D17 scale score reduction rate is ≥25% compared to the baseline period;
- •High suicide risk; history of suicide attempts within one year before screening; suicidal or self-harming behavior during the screening period; score of ≥3 on item 3 (suicide item) of the HAM-D17 scale;
- •Diagnosed with any disease other than depression according to DSM-5, including anxiety disorders, neurodevelopmental disorders, schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive and related disorders, trauma and stress-related disorders, dissociative disorders, anorexia or bulimia nervosa, personality disorders, etc.;
- •Depression secondary to other mental or physical diseases. Note: Other inclusion/exclusion criteria may apply
研究组 & 干预措施
GW117 Tablets 20mg group
Experimental
干预措施: GW117 Tablets (Drug)
placebo
Placebo Comparator
干预措施: Placebo (Drug)
GW117 Tablets 40mg group
Experimental
干预措施: GW117 Tablets (Drug)
GW117 Tablets 60mg group
Experimental
干预措施: GW117 Tablets (Drug)
结局指标
主要结局
The change in Hamilton Depression Scale-17(HAMD-17) total score from baseline
时间窗: 8 week
There are a total of 17 projects in Hamilton Depression Scale-17（HAMD-17）. Scores are distributed on a scale of 0 to 53. Higher scores represent a more severe condition.
次要结局
- The response rate of HAMD-17(8 week)
- The response rate of MADRS(8 week)
- The change inMontgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline(8 week)
- The changes in Clinical Global Impression Scale-Improvement (CGI-I )total score from baseline(8 week)
- The changes in Clinical Globel Impression-Severity(CGI-S) from baseline(8 week)
研究者
研究点 (17)
Loading locations...
相似试验
进行中（未招募）
1 期
A 12-Week Study to Evaluate the Efficacy and Safety of MIN-101 in Adult Patients with Negative Symptoms of Schizophrenia, Followed by 40-Week Open-Label Extensioegative Symptoms of SchizophreniaMedDRA version: 20.0Level: HLGTClassification code 10039628Term: Schizophrenia and other psychotic disordersSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2017-003333-29-BGMinerva Neurosciences, Inc.,501
进行中（未招募）
1 期
A study to evaluate the effect of Benralizumab in Patients with Severe Asthma Uncontrolled.severe uncontrolled asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersMedDRA version: 20.0Level: LLTClassification code 10049106Term: Asthma chronicSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-001040-35-ATAstraZeneca AB630
进行中（未招募）
1 期
Study to Evaluate Efficacy and Safety of Benralizumab in Adult Patients with Mild to Moderate Persistent AsthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2014-004427-40-SKAstraZeneca AB200
进行中（未招募）
1 期
Study to evaluate the safety and effectiveness of Fenfluramine as adjunct therapy in children and young adults with Dravet SyndromeDravet's syndromeMedDRA version: 20.0Level: LLTClassification code 10073682Term: Dravet syndromeSystem Organ Class: 100000004850EUCTR2015-004167-37-DEZogenix International Limited260
进行中（未招募）
1 期
Study to evaluate the safety and effectiveness of Fenfluramine as adjunct therapy in children and young adults with Dravet SyndromeDravet's syndromeMedDRA version: 19.1Level: LLTClassification code 10073682Term: Dravet syndromeSystem Organ Class: 100000004850EUCTR2015-004167-37-SEZogenix International Limited260